<SEC-DOCUMENT>0001193125-17-254670.txt : 20170810
<SEC-HEADER>0001193125-17-254670.hdr.sgml : 20170810
<ACCEPTANCE-DATETIME>20170810172633
ACCESSION NUMBER:		0001193125-17-254670
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20170810
DATE AS OF CHANGE:		20170810

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MICROVISION, INC.
		CENTRAL INDEX KEY:			0000065770
		STANDARD INDUSTRIAL CLASSIFICATION:	ELECTRONIC COMPONENTS, NEC [3679]
		IRS NUMBER:				911600822
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-211869
		FILM NUMBER:		171022372

	BUSINESS ADDRESS:	
		STREET 1:		6244 185TH AVENUE NE, SUITE 100
		CITY:			REDMOND
		STATE:			WA
		ZIP:			98052
		BUSINESS PHONE:		425-936-6847

	MAIL ADDRESS:	
		STREET 1:		6244 185TH AVENUE NE, SUITE 100
		CITY:			REDMOND
		STATE:			WA
		ZIP:			98052

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MICROVISION INC
		DATE OF NAME CHANGE:	19960724
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d441421d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule
424(b)(5) <BR>Registration No. 333-211869<BR> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(To Prospectus dated June&nbsp;22, 2016) </P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g441421g24k04.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>MicroVision, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>4,761,905 Shares of Common Stock </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are offering 4,761,905
shares of our common stock. We have granted the underwriter a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to 714,286 additional shares of our common stock to cover over-allotments, if any. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our shares are traded on The NASDAQ Global Market under the symbol &#147;MVIS.&#148; On August&nbsp;9, 2017, the last sale price of our common stock as
reported on The NASDAQ Global Market was $2.14 per share. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities
involves a high degree of risk. Please see the sections entitled &#147;<A HREF="#supprom441421_4">Risk Factors</A>&#148; on page S-5 of this prospectus supplement, on page&nbsp;2 of the accompanying prospectus, as well as in our periodic reports
filed with the Securities and Exchange Commission and incorporated by reference herein, for a discussion of important risks that you should consider before making an investment decision. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per</B><br><B>Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discount<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.13125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">625,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.96875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,375,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See &#147;Underwriting&#148; on page S-10 of this prospectus supplement for a description of the compensation payable to the underwriter. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or determined if this
prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Ladenburg
Thalmann </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus supplement is
August&nbsp;10, 2017. </B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prospectus Supplement </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom441421_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom441421_2">PROSPECTUS SUPPLEMENT SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom441421_3">NOTE REGARDING FORWARD-LOOKING INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom441421_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom441421_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom441421_6">DESCRIPTION OF SECURITIES WE ARE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom441421_7">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom441421_8">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom441421_9">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom441421_10">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supprom441421_11">DOCUMENTS INCORPORATED BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">S-14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prospectus </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="97%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc288762_1">FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc288762_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc288762_3">THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc288762_4">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc288762_5">RATIO OF COMBINED FIXED CHARGES AND PREFERENCE DIVIDENDS TO
EARNINGS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc288762_6">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc288762_7">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc288762_8">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc288762_9">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc288762_10">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc288762_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc288762_12">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-i </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom441421_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is not complete without, and may not be utilized except in connection with, the accompanying prospectus dated June&nbsp;22, 2016,
and any amendments to such prospectus. This prospectus supplement provides supplemental information regarding the Company, updates and changes information contained in the accompanying prospectus and describes the specific terms of this offering.
The accompanying prospectus gives more general information, some of which may not apply to this offering. We incorporate by reference important information into this prospectus supplement and the accompanying prospectus. You may obtain the
information incorporated by reference into this prospectus supplement and the accompanying prospectus without charge by following the instructions under &#147;Documents Incorporated by Reference&#148; in this prospectus supplement and &#147;Where
You Can Find More Information&#148; in the accompanying prospectus. You should carefully read both this prospectus supplement and the accompanying prospectus, as well as additional information described under &#147;Documents Incorporated by
Reference,&#148; before deciding to invest in shares of our common stock. If the information in, or incorporated by reference in, this prospectus supplement conflicts with information in the accompanying prospectus or a document incorporated by
reference herein or therein, the information in, or incorporated by reference in, this prospectus supplement shall control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All references in this
prospectus supplement to &#147;MicroVision,&#148; &#147;the Company,&#148; &#147;we,&#148; &#147;us&#148; or &#147;our&#148; mean MicroVision, Inc., unless we state otherwise or the context otherwise requires. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>In making your investment decision, you should rely only on the information contained or incorporated by reference in this prospectus supplement, the
accompanying prospectus and any free writing prospectus filed by us with the U.S. Securities and Exchange Commission (&#147;SEC&#148;) and any other offering material we or the underwriter may provide. We have not, and the underwriter has not,
authorized anyone to provide you with different or additional information. If anyone provides you with different or additional information, you should not rely on it. We are not, and the underwriter is not, making an offer to sell these securities
under any circumstance or in any jurisdiction where the offer is not permitted or unlawful. You should assume that the information contained in this prospectus supplement and the accompanying prospectus is accurate only as of their respective dates,
and that any information in documents that we have incorporated by reference is accurate only as of the date of the document incorporated by reference. Our business, financial condition, results of operations, cash flows and prospects may have
changed since those dates. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-ii </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom441421_2"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following summary is qualified in its entirety by, and should be read together with, the more detailed information and our consolidated financial
statements and related notes thereto appearing elsewhere or incorporated by reference in this prospectus supplement and the accompanying prospectus. Before you decide to invest in our securities, you should read the entire prospectus supplement and
the accompanying prospectus carefully, including the risk factors and the financial statements and related notes included or incorporated by reference in this prospectus supplement and the accompanying prospectus. </I></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Our Company </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MicroVision, Inc. is a pioneer in laser beam scanning (LBS) technology that we market under our brand name
PicoP<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. We have developed our proprietary PicoP<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> scanning technology that can be adopted by our customers to create high-resolution
miniature projection and three-dimensional sensing and image capture solutions. PicoP<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> scanning technology is based on our patented expertise in micro-electrical mechanical systems (MEMS),
laser diodes, opto-mechanics, and electronics and how those elements are packaged into a small, low power scanning engine that can display, interact and sense, depending on the needs of the application. For display, the engine can project a
high-quality image on any surface (pico projection), a windshield <FONT STYLE="white-space:nowrap">(head-up</FONT> display or HUD), or a retina (augmented reality or AR). For sensing, we use infrared (IR) lasers to capture three-dimensional data in
the form of a point cloud. Interactivity uses the 3D sensing function and the display function to project an image with which the user can interact as one would use a touch screen. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2016, we announced a growth strategy for 2017 and beyond that includes selling LBS engines to original design manufacturers (ODMs) and original
equipment manufacturers (OEMs) in addition to our strategy of licensing LBS technology to licensees to offer their own solutions. We plan to offer three scanning engines to support a wide array of applications: a small form factor display engine for
consumer products, an interactive display engine for smart Internet of Things (IoT) products, and a <FONT STYLE="white-space:nowrap">mid-range</FONT> light detection and ranging (LiDAR) engine for autonomous machines, industrial products and
robotics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In March 2017, we received a $6.7&nbsp;million order for our small form factor display engine from Ragentek Communication Technology Co.,
Limited (Ragentek), an Asian electronics device manufacturer. We have begun initial shipments of engines to Ragentek at the end of June 2017 to embed in its smartphone product. The smartphone is expected to begin selling in China in the third
quarter of 2017 and later in other markets where the device manufacturer has existing distribution of its products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2017, we signed a contract
with a major technology company to develop an LBS display system. Under this agreement, we would develop a new generation of MEMS, ASICs&nbsp;and related firmware for a high resolution, <FONT STYLE="white-space:nowrap">LBS-based</FONT> product that
the technology company is planning to produce. We would receive up to $24.0&nbsp;million, including $14.0&nbsp;million in fees for development work that is expected to span 21 months and an upfront payment of $10.0&nbsp;million, which payment has
been received.&nbsp;The development fees would be paid contingent on completion of milestones in 2017 and 2018. Upon successful completion of the development program, if the company decides to manufacture the product with the MicroVision display
components, the $10.0&nbsp;million upfront payment would be applied as a discount to future component purchases from us. If the contract is terminated by the technology company for our failure to meet milestones, the $10.0&nbsp;million upfront
payment is subject to repayment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were founded in 1993 as a Washington corporation and reincorporated in 2003 under the laws of the State of Delaware. Our principal office is located at 6244
185th Ave NE, Suite 100, Redmond, WA 98052 and our </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
telephone number is <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">425-936-6847.</FONT></FONT> We maintain a website at www.microvision.com, where general information about us
is available. We do not incorporate the information on our website into this prospectus supplement or the accompanying prospectus and you should not consider it part of this prospectus supplement or the accompanying prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Recent Events </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company has terminated the
Purchase Agreement dated September&nbsp;22, 2016 (the &#147;Common Stock Purchase Agreement&#148;) between the Company and Lincoln Park Capital Fund, LLC. The Common Stock Purchase Agreement is terminable without penalty at the Company&#146;s
election. As a result of the termination of the Common Stock Purchase Agreement, there will be no further sales of our common stock thereunder. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The Offering </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following summary contains basic information about this offering. The summary is not intended to be complete. You should read the full text and more
specific details contained elsewhere in this prospectus supplement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Common stock offered by us</B> </P></TD>
<TD>4,761,905 shares (5,476,191&nbsp;shares if the underwriter&#146;s over-allotment option is exercised in full). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; padding-bottom:3pt; margin-top:-2pt; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Common stock to be outstanding immediately after this offering <SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></B> </P></TD>
<TD>76,357,437&nbsp;shares (77,071,723&nbsp;shares if the underwriter&#146;s over-allotment option is exercised in full). </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Option to purchase additional shares</B> </P></TD>
<TD>We have granted a <FONT STYLE="white-space:nowrap">30-day</FONT> option to the underwriter to purchase up to a total of 714,286 additional shares of our common stock from us at the public offering price, less the underwriting discount payable by
us, to cover over-allotments, if any. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>NASDAQ Global Market symbol</B> </P></TD>
<TD>MVIS </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Use of proceeds</B> </P></TD>
<TD>We estimate that the net proceeds from this offering will be approximately $9.2&nbsp;million, or approximately $10.6&nbsp;million if the underwriter exercises its over-allotment option in full, in each case, after deducting the underwriting
discount and estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We intend to use the net proceeds from the sale of common stock offered by this prospectus supplement for general corporate purposes, which may include, but are not limited to, working capital and capital expenditures.
See &#147;Use of Proceeds.&#148; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Risk factors</B> </P></TD>
<TD>Investing in our common stock involves a high degree of risk. See &#147;Risk Factors.&#148; </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The number of shares of common stock to be outstanding after this offering is based on 71,595,532 shares outstanding as of July&nbsp;31, 2017 and excludes, as of that date, the following: </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">5,234,278 shares of our common stock issuable upon exercise of outstanding options, of which approximately 2,522,740 were exercisable at a weighted average exercise price of $3.96 per share, under our 2013 Incentive
Plan, as amended, or the Incentive Plan, and our Independent Director Stock Option Plan; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">60,000 shares of our common stock underlying unvested stock awards; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,973,000 shares of our common stock issuable upon exercise of outstanding warrants, all of which were exercisable at a weighted average exercise price of $2.47 per share; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">634,609 shares of our common stock reserved for issuance pursuant to the Incentive Plan. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise
indicated, this prospectus supplement assumes no exercise by the underwriter of its over-allotment option. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom441421_3"></A>NOTE REGARDING FORWARD-LOOKING INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the accompanying prospectus and the documents incorporated by reference herein and therein contain forward-looking statements,
within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and is subject to the safe harbor created by that
section. Such statements may include, but are not limited to, projections of revenues, income or loss, capital expenditures, plans for product development and our cooperative arrangements, future operations, financing needs or plans, as well as
assumptions relating to the foregoing. The words &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;goal,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;project,&#148; and similar expressions identify
forward-looking statements, which speak only as of the date the statement was made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These forward-looking statements may include those relating to
potential applications and features of our technology and involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in our forward-looking statements include the following: our
ability to raise additional capital when needed; products incorporating our PicoP<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> display engine may not achieve market acceptance, commercial partners may not perform under agreements as
anticipated, we may be unsuccessful in identifying parties interested in paying any amounts or amounts we deem desirable for the purchase or license of intellectual property assets, our or our customers&#146; failure to perform under open purchase
orders; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and
protect our proprietary technologies; the ability to obtain additional contract awards; the timing of commercial product launches and delays in product development; the ability to achieve key technical milestones in key products; dependence on third
parties to develop, manufacture, sell and market our products; potential product liability claims; and other risk factors identified from time to time in our SEC reports, including our Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> filed with the SEC. Except as expressly required by federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information,
future events, changes in circumstances or any other reason. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom441421_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>An investment in our securities involves a high degree of risk. You should carefully consider all of the information in this prospectus supplement and the
accompanying prospectus, including the risks and uncertainties described below, and all other information included or incorporated by reference in this prospectus supplement and the accompanying prospectus, before you decide whether to purchase our
securities. The risks and uncertainties we describe are not the only ones facing us. Additional risks not presently known to us or that we currently deem immaterial may also impair our business operations. If any of these risks were to occur, our
business, financial condition or results of operations would likely suffer. In that event, the trading price of our common stock could decline and you could lose all or part of your investment. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Common Stock and this Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We have broad discretion in the use of the net proceeds from this offering and may not use them effectively. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our management will have broad discretion in the application of the net proceeds from this offering and could spend the proceeds in ways that do not
necessarily improve our results of operations or enhance the value of our common stock. Our failure to apply these funds effectively could have a material adverse effect on our business, financial condition, operating results and cash flow, and
could cause the price of our common stock to decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>If you purchase the common stock sold in this offering, you will experience immediate and
substantial dilution in your investment. You will experience further dilution if we issue additional equity securities in future fundraising transactions. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since the price per share of our common stock being offered is substantially higher than the net tangible book value per share of our common stock, you will
suffer substantial dilution with respect to the net tangible book value of the common stock you purchase in this offering. Based on the public offering price of $2.10 per share and our net tangible book value as of June&nbsp;30, 2017, if you
purchase shares of common stock in this offering, you will suffer immediate and substantial dilution of $1.94 per share with respect to the net tangible book value of the common stock. See the section entitled &#147;Dilution&#148; elsewhere in this
prospectus supplement for a more detailed discussion of the dilution you will incur if you purchase common stock in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we issue additional
common stock, or securities convertible into or exchangeable or exercisable for common stock following the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement we entered into with the underwriter as described in the section
entitled &#147;Underwriting&#148; elsewhere in this prospectus supplement, our stockholders, including investors who purchase shares of common stock in this offering, could experience additional dilution, and any such issuances may result in
downward pressure on the price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Future sales of shares by existing stockholders could cause our stock price to decline. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that
the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of July&nbsp;31,
2017, we had outstanding options to purchase an aggregate of 5,234,278 shares of our common stock, of which approximately 2,522,740 were exercisable at a weighted average exercise price of $3.96 per share, and outstanding warrants to purchase an
aggregate of 1,973,000 shares of our common stock, all of which are exercisable at a weighted average exercise price of $2.47 per share. The exercise of such outstanding options and warrants will result in further dilution of your investment. If our
existing stockholders sell substantial amounts of our common stock in the public market, or if the public perceives that such sales could occur, this could have an adverse impact on the market price of our common stock, even if there is no
relationship between such sales and the performance of our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We do not currently intend to pay dividends on our common stock, and any return to investors is expected to
come, if at all, only from potential increases in the price of our common stock. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the present time, we intend to use available funds to finance our
operations. Accordingly, while payment of dividends rests within the discretion of our board of directors, no cash dividends on our common shares have been declared or paid by us and we have no intention of paying any such dividends in the
foreseeable future. Any return to investors is expected to come, if at all, only from potential increases in the price of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom441421_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that the net proceeds to us from this offering will be approximately $9.2&nbsp;million (or approximately $10.6&nbsp;million if the
underwriter&#146;s over-allotment option is exercised in full), in each case after deducting the underwriting discount and estimated offering expenses payable by us. We anticipate that the net proceeds from the sale of the securities offered under
this prospectus supplement will be used for general corporate purposes, which may include, but are not limited to, working capital and capital expenditures. Pending the application of the net proceeds, we expect to invest the proceeds in
investment-grade, interest-bearing instruments or other securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom441421_6"></A>DESCRIPTION OF SECURITIES WE ARE OFFERING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are offering 4,761,905 shares of our common stock. We have granted the underwriter an option to purchase up to 714,286 additional shares of our common
stock to cover over-allotments, if any. The material terms and provisions of our common stock are described under the caption &#147;Description of Capital Stock&#148; starting on page&nbsp;4 of the accompanying prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom441421_7"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you invest in our securities, your interest will be diluted by an amount equal to the difference between the public offering price and the net tangible
book value per share of our common stock after this offering. We calculate net tangible book value per share by dividing our net tangible book value (total assets less intangible assets and total liabilities) by the number of outstanding shares of
common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our net tangible book value at June&nbsp;30, 2017 was $3,165,000, or $0.04 per share of common stock. After giving effect to the sale of
4,761,905 shares of common stock, and our receipt of the expected net proceeds from the sale of those shares, our adjusted net tangible book value at June&nbsp;30, 2017 would be $12,325,000, or $0.16 per share. This represents an immediate increase
in <FONT STYLE="white-space:nowrap">as-adjusted</FONT> net tangible book value of $0.12 per share to existing shareholders and an immediate and substantial dilution of $1.94 per share to new investors. The following table illustrates this per share
dilution: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net tangible book value per share at June&nbsp;30, 2017</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.04</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Increase in net tangible book value per share attributable to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">As-adjusted</FONT> net tangible book value per share as of
June&nbsp;30, 2017, after giving effect to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dilution per share to new investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information above assumes that the underwriter does not exercise its over-allotment option.&nbsp;If the underwriter
exercises its over-allotment option in full, the <FONT STYLE="white-space:nowrap">as-adjusted</FONT> net tangible book value after this offering would be approximately $0.18 per share, representing an increase in net tangible book value of
approximately $0.14 per share to existing shareholders and immediate dilution in net tangible book value of approximately $1.92 per share to new investors purchasing our common stock in this offering at the public offering price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table and discussion above are based on 71,595,532 shares of our common stock outstanding as of June&nbsp;30, 2017 and excludes, as of that date, the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">5,244,053 shares of our common stock issuable upon exercise of outstanding options, of which approximately 2,514,040 were exercisable at a weighted average exercise price of 3.96 per share, under our 2013 Incentive
Plan, as amended, or the Incentive Plan, and our Independent Director Stock Option Plan; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">60,000 shares of our common stock underlying unvested stock awards; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,973,000 shares of our common stock issuable upon exercise of outstanding warrants, all of which were exercisable at a weighted average exercise price of $2.47 per share; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">624,834 shares of our common stock reserved for issuance pursuant to the Incentive Plan. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that
any of the outstanding warrants or options are exercised, there will be further dilution to new investors. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have
sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity securities, the issuance of these securities could result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom441421_8"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriter named below has agreed to buy, subject to the terms of the underwriting agreement, the number of shares of common stock listed opposite its
name below. The underwriter is committed to purchase and pay for all of the shares if any are purchased, other than those shares covered by the over-allotment option described below. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:43.10pt; font-size:8pt; font-family:Times New Roman"><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ladenburg Thalmann&nbsp;&amp; Co. Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,761,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriter has advised us that it proposes to offer the shares of common stock to the public at a price of $2.10 per
share. The underwriter proposes to offer the shares of common stock to certain dealers at the same price less a concession of not more than $0.07875 per share. After the offering, these figures may be changed by the underwriter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares sold in this offering are expected to be ready for delivery against payment in immediately available funds on or about August&nbsp;15, 2017,
subject to customary closing conditions. The underwriter may reject all or part of any order. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have granted to the underwriter an option to purchase up
to an additional 714,286&nbsp;shares of common stock from us at the same price to the public, and with the same underwriting discount, as set forth in the table below. The underwriter may exercise this option, in whole or in part, any time during
the <FONT STYLE="white-space:nowrap">30-day</FONT> period after the date of this prospectus supplement, but only to cover over-allotments, if any. To the extent the underwriter exercises the option, the underwriter will become obligated, subject to
certain conditions, to purchase the shares for which it exercises the option. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Commissions and Discounts </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below summarizes the underwriting discounts that we will pay to the underwriter. These amounts are shown assuming both no exercise and full exercise
of the over-allotment option. In addition to the underwriting discount, we have agreed to pay up to $100,000 of the fees and expenses of the underwriter, which may include the fees and expenses of counsel to the underwriter. The fees and expenses of
the underwriter that we have agreed to reimburse are not included in the underwriting discounts set forth in the table below. The underwriter has not received and will not receive from us any other item of compensation or expense in connection with
this offering considered by the Financial Industry Regulatory Authority, Inc., or FINRA, to be underwriting compensation under its rules. The underwriting discount and other items of compensation the underwriter will receive were determined through
arms&#146; length negotiations between us and the underwriter. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;with<BR>no</B><br><B>Over-<BR>Allotment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;with<BR>Over-<BR>Allotment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Underwriting discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.13125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">625,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">718,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have agreed to pay Rodman &amp; Renshaw, a unit of H.C. Wainwright and Co., LLC, and Aegis Capital Corp. (together, the
&#147;Advisors&#148;) financial advisory fees in the amount of $100,000 in the aggregate in connection with the offering, which we have not included in the underwriting commissions and discounts. The Advisors are not engaged in, nor affiliated with
any entity that is engaged in, the solicitation or distribution of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimate that the total expenses of this offering, excluding
underwriting discounts, will be $215,000. This includes $100,000 of fees and expenses of the underwriter. These expenses are payable by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also have agreed to indemnify the underwriter against certain liabilities, including civil liabilities under the Securities Act, or to contribute to
payments that the underwriter may be required to make in respect of those liabilities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Sales of Similar Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and each of our directors and officers have agreed not to offer, sell, agree to sell, directly or indirectly, or otherwise dispose of any shares of common
stock or any securities convertible into or exchangeable for shares of common stock without the prior written consent of the underwriter for a period of 90 days after the date of this prospectus supplement. These
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements provide certain exceptions and their restrictions may be waived at any time by the underwriter. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Price Stabilization, Short Positions and Penalty Bids </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To
facilitate this offering, the underwriter may engage in transactions that stabilize, maintain or otherwise affect the price of our common stock during and after the offering. Specifically, the underwriter may create a short position in our common
stock for its own accounts by selling more shares of common stock than we have sold to the underwriter. The underwriter may close out any short position by purchasing shares in the open market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the underwriter may stabilize or maintain the price of our common stock by bidding for or purchasing shares in the open market and may impose
penalty bids. If penalty bids are imposed, selling concessions allowed to broker-dealers participating in this offering are reclaimed if shares previously distributed in this offering are repurchased, whether in connection with stabilization
transactions or otherwise. The effect of these transactions may be to stabilize or maintain the market price of our common stock at a level above that which might otherwise prevail in the open market. The imposition of a penalty bid may also affect
the price of our common stock to the extent that it discourages resales of our common stock. The magnitude or effect of any stabilization or other transactions is uncertain. These transactions may be effected on The NASDAQ Global Market or otherwise
and, if commenced, may be discontinued at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this offering, the underwriter and selling group members may also engage in
passive market making transactions in our common stock on The NASDAQ Global Market. Passive market making consists of displaying bids on The NASDAQ Global Market limited by the prices of independent market makers and effecting purchases limited by
those prices in response to order flow. Rule 103 of Regulation M promulgated by the SEC limits the amount of net purchases that each passive market maker may make and the displayed size of each bid. Passive market making may stabilize the market
price of our common stock at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither we nor the underwriter make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may
have on the price of our common stock. In addition, neither we nor the underwriter make any representation that the underwriter will engage in these transactions or that any transaction, if commenced, will not be discontinued without notice. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Electronic Offer, Sale and Distribution of Shares </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
underwriter or syndicate members may facilitate the marketing of this offering online directly or through one of their affiliates. In those cases, prospective investors may view offering terms and a prospectus supplement online and place orders
online or through their financial advisors. Such websites and the information contained on such websites, or connected to such sites, are not incorporated into and are not a part of this prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Relationships </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriter and its affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and
investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. The underwriter has in the past, and may in the future, engage in investment banking and other
commercial dealings in the ordinary course of business with us or our affiliates. The underwriter has in the past, and may in the future, receive customary fees and commissions for these transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the ordinary course of their various business activities, the underwriter and its affiliates may make or hold a broad array of investments and actively
trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers, and such investment and securities activities may involve securities
and/or instruments of the issuer. The underwriter and its affiliates may also make investment recommendations and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to
clients that it acquires, long and/or short positions in such securities and instruments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling Restrictions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Canada.</B> The offering of the common stock in Canada is being made on a private placement basis in reliance on exemptions from the prospectus requirements
under the securities laws of each applicable Canadian province and territory where the common stock may be offered and sold, and therein may only be made with investors that are purchasing as principal and that qualify as both an &#147;accredited
investor&#148; as such term is defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> - Prospectus Exemptions, and as a &#147;permitted client&#148; as such term is defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103</FONT> - Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any offer and sale of the common stock in any province or territory of Canada may only be made through a dealer that is
properly registered under the securities legislation of the applicable province or territory wherein the common stock is offered and/or sold or, alternatively, by a dealer that qualifies under and is relying upon an exemption from the registration
requirements therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any resale of the common stock by an investor resident in Canada must be made in accordance with applicable Canadian securities
laws, which may require resales to be made in accordance with prospectus and registration requirements, statutory exemptions from the prospectus and registration requirements or under a discretionary exemption from the prospectus and registration
requirements granted by the applicable Canadian securities regulatory authority. These resale restrictions may under certain circumstances apply to resales of the common stock outside of Canada. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>European Economic Area. </B>In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive each, a Relevant
Member State, no offer to the public of any of our shares of common stock will be made, other than under the following exemptions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity that is a qualified investor as defined in the Prospectus Directive; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 100 or, if the Relevant Member State has implemented the relevant provision of the 2010 PD Amending Directive, 150, natural or legal persons (other than qualified investors as defined in the Prospectus
Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the issuer for any such offer; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Article 3(2) of the Prospectus Directive, provided that no such offer of shares of our common stock will result in a requirement for the publication by us or any underwriter of
a prospectus pursuant to Article 3 of the Prospectus Directive or any supplementary prospectus pursuant to Article 16 of the Prospectus Directive. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to any shares of our common stock in any Relevant Member
State means the communication in any form and by any means of sufficient </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
information on the terms of the offer so as to enable an investor to decide to purchase or subscribe for any shares of common stock, as the same may be varied in that Member State by any measure
implementing the Prospectus Directive in that Member State. The expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (and amendments thereto, including the 2010 PD Amending Directive, to the extent implemented in the Relevant
Member State), and includes any relevant implementing measure in the Relevant Member State, and the expression &#147;2010 PD Amending Directive&#148; means Directive 2010/73/EU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>United Kingdom.</B> This document is not an approved prospectus for the purposes of section 85 of the UK Financial Services and Markets Act 2000, as
amended, or FSMA, and a copy of it has not been, and will not be, delivered to or approved by the UK Listing Authority or approved by any other authority which could be a competent authority for the purposes of the Prospectus Directive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is only being distributed to, and is only directed at, persons in the United Kingdom that are &#147;qualified investors&#148;
within the meaning of section 86(7) of FSMA that are also (i)&nbsp;investment professionals falling within Article 19(5) of the UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended, or the Order, and/or
(ii)&nbsp;high net worth companies, unincorporated associations or partnerships and the trustees of high value trusts falling within Article 49(2)(a) to (d)&nbsp;of the Order and other persons to whom it may lawfully be communicated (each such
person being referred to as a &#147;relevant person&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any person in the United Kingdom that is not a relevant person should not act or rely on
these documents or any of their contents. Any investment, investment activity or controlled activity to which this document relates is available in the United Kingdom only to relevant persons and will be engaged in only with such persons.
Accordingly, this document has not been approved by an authorized person, as would otherwise be required by Section&nbsp;21 of FSMA. Any purchaser of shares of common stock resident in the United Kingdom will be deemed to have represented to us and
the underwriter, and acknowledge that each of us and the underwriter are relying on such representation, that it, or the ultimate purchaser for which it is acting as agent, is a relevant person. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent and
registrar for our common stock is American Stock Transfer and Trust Company, LLC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom441421_9"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the common stock being offered hereby will be passed upon by Ropes&nbsp;&amp; Gray LLP, Boston, Massachusetts. Lowenstein Sandler LLP, New
York, New York, is acting as counsel for the underwriter in connection with this offering. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom441421_10"></A>EXPERTS
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our consolidated financial statements appearing in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2016, and the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2016, have been audited by Moss Adams LLP, an independent registered public accounting firm, as stated in their reports, which are
incorporated herein by reference. Such consolidated financial statements have been so incorporated in reliance upon the report of such firm (which report expresses an unqualified opinion and includes an explanatory paragraph regarding a going
concern emphasis) given upon their authority as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supprom441421_11"></A>DOCUMENTS
INCORPORATED BY REFERENCE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and special reports, proxy statements and other information with the Securities and Exchange
Commission, or the SEC. These documents are on file with the SEC. You may read and copy any document we file at the SEC&#146;s public reference room at 100 F Street, N.E., Washington, D.C. 20549. You can request copies of these documents by
contacting the SEC and paying a fee for the copying cost. Please call the SEC at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-SEC-0330</FONT></FONT></FONT> for further information on the
public reference room. Our SEC filings are also available to the public from the SEC&#146;s website at www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement and the
accompanying prospectus are part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> including amendments, relating to the common stock offered by this prospectus supplement and the accompanying prospectus, which have
been filed with the SEC. This prospectus supplement and the accompanying prospectus do not contain all of the information set forth in the registration statement and the exhibits and schedules thereto, certain parts of which are omitted in
accordance with the rules and regulations of the SEC. Statements contained in this prospectus supplement and the accompanying prospectus as to the contents of any contract or other document referred to are not necessarily complete and in each
instance reference is made to the copy of that contract or other document filed as an exhibit to the registration statement. For further information about us and the common stock offered by this prospectus supplement and the accompanying prospectus
we refer you to the registration statement and the exhibits and schedules which may be obtained as described above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to
&#147;incorporate by reference&#148; the information contained in documents that we file with them, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is
considered to be part of this prospectus supplement and the accompanying prospectus. Information in the accompanying prospectus supersedes information incorporated by reference that we filed with the SEC before the date of the prospectus, and
information in this prospectus supplement supersedes information incorporated by reference that we filed with the SEC before the date of this prospectus supplement, while information that we file later with the SEC will automatically update and
supersede the information in this prospectus supplement and the accompanying prospectus or incorporated by reference. We incorporate by reference the documents listed below and any future filings we will make with the SEC under Sections 13(a),
13(c), 14 or 15(d) of the Exchange Act prior to the time that all securities covered by this prospectus supplement have been sold; provided, however, that we are not incorporating any information furnished under any of Item 2.02 or Item 7.01 of any
current report on Form <FONT STYLE="white-space:nowrap">8-K:</FONT> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2016 filed with the SEC on March&nbsp;6, 2017; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended March&nbsp;31, 2017 and June&nbsp;30, 2017 filed with the SEC on April&nbsp;28, 2017 and August&nbsp;3, 2017,
respectively; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our Definitive Proxy Statement on Schedule 14A filed with the SEC on April&nbsp;24, 2017; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on February&nbsp;10, 2017, March&nbsp;28, 2017, May&nbsp;4, 2017, June&nbsp;9, 2017, June&nbsp;13, 2017 and August&nbsp;10,
2017; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The description of our common stock set forth in Amendment No.&nbsp;1 to our Registration Statement on Form <FONT STYLE="white-space:nowrap">SB-2</FONT> (Registration No. <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">333-5276-LA),</FONT></FONT> including any amendment or report filed for the purpose of updating such description, as incorporated by reference in our Registration Statement on Form
<FONT STYLE="white-space:nowrap">8-A</FONT> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;0-21221).</FONT> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will promptly
provide, without charge to each person (including any beneficial owners) who receives a copy of this prospectus, upon written or oral request, a copy of any or all of the documents incorporated by reference in this prospectus supplement. Requests
should be directed to: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MicroVision, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6244 185<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Avenue NE, Suite 100 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Redmond, Washington 98052 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(425) <FONT STYLE="white-space:nowrap">936-6847</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You can also find these filings on our website at www.microvision.com. We are not incorporating the information on our website other than these filings into
this prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">S-15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$35,000,000 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>MicroVision, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred
Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell
from time to time up to $35,000,000 of our common stock, preferred stock, or warrants in one or more transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide
specific terms of these securities and offerings in supplements to this prospectus. You should read this prospectus and any supplement carefully before you invest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is traded on The NASDAQ Global Market under the symbol &#147;MVIS.&#148; On June&nbsp;20, 2016, the closing price of our
common stock on The NASDAQ Global Market was $1.85 per share. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>The
securities offered in this prospectus involve a high degree of risk. You should carefully consider the information under the heading &#147;<A HREF="#toc288762_2">Risk Factors</A>&#148; set forth herein on page 2 and in our filings made with the
Securities and Exchange Commission, which are incorporated by reference in this prospectus, in determining whether to purchase our securities. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our executive offices are located at 6244 185<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Avenue NE, Suite 100, Redmond, Washington
98052, and our telephone number is (425)&nbsp;936-6847. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the
Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is June&nbsp;22, 2016. </B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="95%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc288762_1">FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc288762_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc288762_3">THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc288762_4">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc288762_5">RATIO OF COMBINED FIXED CHARGES AND PREFERENCE DIVIDENDS TO
EARNINGS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc288762_6">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc288762_7">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc288762_8">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc288762_9">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc288762_10">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc288762_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc288762_12">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc288762_1"></A>FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the documents incorporated by reference in this prospectus contain forward-looking statements, within the meaning of
Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and is subject to the safe harbor created by that section. Such
statements may include, but are not limited to, projections of revenues, income or loss, capital expenditures, plans for product development and cooperative arrangements, future operations, financing needs or plans of MicroVision, as well as
assumptions relating to the foregoing. The words &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;goal,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;project,&#148; &#147;will,&#148; and similar
expressions identify forward-looking statements, which speak only as of the date the statement was made. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements
are not guarantees of future performance. Factors that could cause actual results to differ materially from those projected in our forward-looking statements include the following: our ability to obtain financing; market acceptance of our
technologies and products; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual
property rights and protect our proprietary technologies; the ability to obtain additional contract awards and to develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key
products; and other factors set forth in the section entitled &#147;Risk Factors&#148; below, and in the documents incorporated by reference into this prospectus. These factors are not intended to represent a complete list of the general or specific
factors that may affect us. It should be recognized that other factors, including general economic factors and business strategies, may be significant, now or in the future, and the factors set forth in this prospectus may affect us to a greater
extent than indicated. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth in or incorporated into this prospectus. Except as required by
law, we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc288762_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should carefully consider the specific risks set forth under the caption &#147;Risk Factors&#148; in our most recent annual report on Form
10-K and quarterly report on Form 10-Q, each as amended or supplemented, which are incorporated by reference in this prospectus, as the same may be amended, supplemented or superseded by our subsequent quarterly reports or other filings, including
filings after the date hereof, with the Securities and Exchange Commission under the Exchange Act. The risks and uncertainties we describe are not the only ones facing us. Additional risks not presently known to us or that we currently deem
immaterial may also impair our business operations. If any of these risks were to occur, our business, financial condition or results of operations would likely suffer. In that event, the trading price of our common stock could decline, and you
could lose all or part of your investment. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc288762_3"></A>THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MicroVision, Inc. is a pioneer in laser beam scanning (LBS) technology that we market under our brand name PicoP<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. We have developed our proprietary PicoP scanning technology that can be adopted by our customers to create high-resolution miniature projection and three-dimensional sensing and image capture
solutions that use laser diodes as the light source.&nbsp;Our PicoP scanning technology incorporates our patented expertise in two-dimensional Micro-Electrical Mechanical Systems (MEMS), lasers, optics, and electronics to create a small form factor
scanning engine with lower power needs than many other technologies that projects high-quality video and still image and/or uses depth sensing to capture three-dimensional data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have licensed our patented PicoP scanning technology to other companies for incorporation into their scanning engines for
projection.&nbsp;We sell our licensees key components needed to produce the laser scanning engines and/or license our technology to collect a royalty for each scanning engine they sell.&nbsp;Companies to whom we license our Pico scanning technology
are typically original design manufacturers (ODMs) or original equipment manufacturers (OEMs) who are in the business of making component parts or products ready for sale to end users.&nbsp;To date, we have primarily focused on the consumer
electronics market, however, we believe that our technology creates a platform that can support multiple applications and markets including enterprise, medical, industrial and automotive. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc288762_4"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the applicable prospectus supplement, we anticipate that the net proceeds from the sale of the securities
offered under this prospectus will be used for general corporate purposes, which may include, but are not limited to, working capital, capital expenditures, and acquisitions of other technologies. The prospectus supplement relating to specific sales
of our securities hereunder will set forth our intended use for the net proceeds we receive from the sales. Pending the application of the net proceeds, we expect to invest the proceeds in investment-grade, interest-bearing instruments or other
securities. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc288762_5"></A>RATIO OF COMBINED FIXED CHARGES AND PREFERENCE DIVIDENDS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO EARNINGS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we have
incurred losses in each of the periods presented below, our earnings were inadequate to cover fixed charges and preference dividends, if any, by the following amounts (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>THREE&nbsp;MONTHS&nbsp;ENDED<BR>MARCH 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>FISCAL&nbsp;YEAR&nbsp;ENDED</B><br><B>DECEMBER 31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2011</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2012</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional earnings required to cover fixed charges</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">35,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">22,693</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13,178</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our deficiency of combined fixed charges and preference dividends to earnings for each of the periods referred
to above has been computed on a consolidated basis and should be read in conjunction with the consolidated financial statements, including the notes thereto, and other information set forth in the reports filed by us with the SEC. Please refer to
Exhibit 12.1 filed with the registration statement of which this prospectus constitutes a part for additional information regarding the ratio of earnings to cover fixed charges and preference dividends, if any. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc288762_6"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Certificate of Incorporation, as amended, authorizes us to issue 100,000,000 shares of common stock, $0.001 par value per share, and
25,000,000 shares of preferred stock, $0.001 par value per share. As of June 2, 2016, there were 51,654,573 shares of common stock, and no shares of preferred stock, outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Common Stock.</I> All outstanding common stock is, and any stock issued under this prospectus will be, fully paid and nonassessable.
Subject to the rights of the holders of our outstanding preferred stock, holders of common stock: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">are entitled to any dividends validly declared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">will share ratably in our net assets in the event of a liquidation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">are entitled to one vote per share. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The common stock has no conversion rights. Holders of
common stock have no preemption, subscription, redemption, or call rights related to those shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">American Stock Transfer&nbsp;&amp;
Trust Company is the transfer agent and registrar for our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Preferred Stock.</I> The Board of Directors has the authority,
without further action by the shareholders, to issue shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof, including dividend rights, conversion rights, voting rights, terms of
redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series. The issuance of preferred stock could adversely affect the voting power of holders of our common stock and
the likelihood that such holders will receive dividend payments and payments upon liquidation may have the effect of delaying, deferring or preventing a change in control of MicroVision, which could depress the market price of our common stock. If
we offer preferred stock, the terms of that series of preferred stock will be set forth in the prospectus supplement relating to that series. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc288762_7"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue warrants for the purchase of common stock, preferred stock, warrants or units of any combination of the foregoing securities.
Each series of warrants will be issued under a warrant agreement all as set forth in the prospectus supplement or term sheet relating to the warrants offered hereby. A copy of the form of warrant agreement, including any form of warrant certificates
representing the warrants, reflecting the provisions to be included in the warrant agreements and/or warrant certificates that will be entered into with respect to particular offerings of warrants, will be filed as an exhibit to a Form 8-K to be
incorporated into the registration statement of which this prospectus forms a part prior to the issuance of any warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable
prospectus supplement or term sheet will describe the terms of the warrants offered thereby, any warrant agreement relating to such warrants and the warrant certificates, including but not limited to the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the offering price or prices; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the aggregate amount of securities that may be purchased upon exercise of such warrants and minimum number of warrants that are exercisable; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of securities, if any, with which such warrants are being offered and the number of such warrants being offered with each security; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date on and after which such warrants and the related securities, if any, will be transferable separately; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amount of securities purchasable upon exercise of each warrant and the price at which the securities may be purchased upon such exercise, and events or conditions under which the amount of securities may be subject
to adjustment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date on which the right to exercise such warrants shall commence and the date on which such right shall expire; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the circumstances, if any, which will cause the warrants to be deemed to be automatically exercised; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any material risk factors, if any, relating to such warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the identity of any warrant agent; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other terms of such warrants. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the exercise of any warrants, holders of such
warrants will not have any rights of holders of the securities purchasable upon such exercise, including the right to receive payments of dividends, if any, on the securities purchasable upon such exercise, statutory appraisal rights or the right to
vote such underlying securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prospective purchasers of warrants should be aware that material U.S. federal income tax, accounting and
other considerations may be applicable to instruments such as warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc288762_8"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>General.</I> We may sell the securities offered hereby directly to one or more purchasers, through agents, or through underwriters or
dealers designated from time to time. The distribution of securities may be effected from time to time in one or more transactions at a fixed price or prices (which may be changed from time to time), at market prices prevailing at the times of sale,
at prices related to these prevailing market prices or at negotiated prices. The applicable prospectus supplement will describe the terms of the offering of the securities, including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms of the securities to which such prospectus supplement relates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the name or names of any underwriters, if any; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchase price of the securities and the proceeds we will receive from the sale; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any underwriting discounts and other items constituting underwriters&#146; compensation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any discounts or concessions allowed or reallowed or paid to dealers. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Underwriters named in
the prospectus supplement, if any, are only underwriters of the securities offered with the prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Sales Directly to
Purchasers.</I> We may enter into agreements directly with one or more purchasers. Such agreements may provide for the sale of securities at a fixed price, based on the market price of the securities or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Use of Underwriters and Agents</I>. If underwriters are used in the sale of securities, they will acquire the securities for their own
accounts and may resell them from time to time in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The securities may be offered to the public through underwriting syndicates represented
by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters will be obligated to purchase all the securities offered by the prospectus supplement. Any public offering price and any discounts or
concessions allowed or reallowed or paid to dealers may change from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Securities may be sold directly to or through agents
from time to time. Any agent involved in the offering and sale of securities will be named and any commissions paid to the agent will be described in the prospectus supplement. Unless the prospectus supplement states otherwise, any agent will act on
a best-efforts basis for the period of its appointment. Agents or underwriters may be authorized to solicit offers by certain types of institutional investors to purchase securities at the public offering price set forth in the prospectus supplement
pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. The conditions to these contracts and the commissions paid for solicitation of these contracts will be described in the prospectus
supplement. We may engage in &#147;at the market&#148; offerings only of our common stock. An &#147;at the market&#148; offering is defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, or the Securities Act, as an offering of
equity securities into an existing trading market for outstanding shares of the same class at other than a fixed price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Deemed
Underwriters.</I> In connection with the sale of the securities offered with this prospectus, underwriters, dealers or agents may receive compensation from us or from purchasers of the securities for whom they may act as agents, in the form of
discounts, concessions or commissions. The underwriters, dealers or agents which participate in the distribution of the securities may be deemed to be underwriters under the Securities Act and any discounts or commissions received by them and any
profit on the resale of the securities received by them may be deemed to be underwriting discounts and commissions under the Securities Act. Anyone deemed to be an underwriter under the Securities Act may be subject to statutory liabilities,
including Sections 11, 12 and 17 of the Securities Act and Rule 10b-5 under the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Indemnification and Other Relationships</I>. We may provide agents and underwriters with
indemnification against certain civil liabilities, including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to such liabilities. Agents and underwriters may engage
in transactions with, or perform services for, us in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Listing of Securities.</I> Except as indicated
in the applicable prospectus supplement, the securities are not expected to be listed on a securities exchange or market, except for the common stock, which will be listed on The NASDAQ Global Market, and any underwriters or dealers will not be
obligated to make a market in securities. We cannot predict the activity or liquidity or any trading in the securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc288762_9"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and special reports, proxy statements and other information with the SEC. You may read and copy any document we file
at the SEC at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information. Our SEC filings are also available to the public from the SEC&#146;s website at http://www.sec.gov. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc288762_10"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; the information we file with them, which means that we can disclose important
information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus, and the information that we file later with the SEC will automatically update and supersede this
information. We incorporate by reference the documents listed below and any future filings we will make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the time that all securities covered by this prospectus have
been sold; provided, however, that we are not incorporating any information furnished under any of Item&nbsp;2.02 or Item&nbsp;7.01 (including exhibits furnished under Item&nbsp;9.01 in connection with information furnished under Item&nbsp;2.02 or
Item&nbsp;7.01) of any current report on Form&nbsp;8-K: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our annual report on Form 10-K for the year ended December&nbsp;31, 2015, filed with the SEC on March&nbsp;8, 2016; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our quarterly report on Form 10-Q for the quarter ended March&nbsp;31, 2016, filed with the SEC on April&nbsp;27, 2016; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our current reports on Form 8-K filed with the SEC on March&nbsp;22, 2016 and June&nbsp;3, 2016; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Any other filings we make pursuant to the Exchange Act after the filing date of the initial registration statement and prior to effectiveness of the registration statement; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The description of our common stock set forth in Amendment No.&nbsp;1 to our registration statement on Form SB-2 (Registration No.&nbsp;333-5276-LA), including any amendment or report filed for the purpose of updating
such description, as incorporated by reference in our registration statement on Form 8-A (Registration No. 0-21221). </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You
may request a copy of these filings, at no cost, by writing or telephoning us at the following address: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><B>MicroVision, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><B>6244 185th Avenue NE, Suite 100 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><B>Redmond, Washington 98052 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><B>Attention: Investor Relations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman"><B>(425) 936-6847 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This
prospectus is part of a registration statement that we have filed with the SEC. You should rely only on the information or representations provided in this prospectus. We have not authorized anyone to provide you with different information. We are
not making an offer of these securities in any state where the offer is not permitted. You should not assume that the information in this prospectus is accurate as of any date other than the date on the front of the document. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc288762_11"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the purpose of this offering, Ropes&nbsp;&amp; Gray LLP, Boston, Massachusetts, is giving its opinion on the validity of the securities
offered hereby. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc288762_12"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our consolidated financial statements appearing in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2015, and the
effectiveness of our internal control over financial reporting as of December&nbsp;31, 2015, have been audited by Moss Adams LLP, an independent registered public accounting firm, as stated in their reports, which are incorporated herein by
reference. Such consolidated financial statements have been so incorporated in reliance upon the report of such firm (which report expresses an unqualified opinion and includes an explanatory paragraph regarding a going concern emphasis) given upon
their authority as experts in accounting and auditing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:50pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>4,761,905&nbsp;Shares </B></P>
<P STYLE="font-size:40pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g441421g24k04.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:40pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:32pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
SUPPLEMENT </B></P> <P STYLE="font-size:20pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:40pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>Ladenburg Thalmann </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:98pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>August&nbsp;10, 2017 </B></P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g441421g24k04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g441421g24k04.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( '@
MN0,!$0 "$0$#$0'_Q  ?  $  @(# 0$! 0          "0H("P0%!P8# @'_
MQ  Y$  !! (" 00! P$$" <    % @,$!@$'  @)"A$2$Q05%B$C%R(D01@F
M,3)"5973&24H0U>7U?_$ !@! 0 # 0                 ! @,$_\0 ,A$
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MB-'D.(?/8[8R^Q2D]/GB7 M)^DBZ>B-+,!M_[CW/<=\%@OR-777)L!5:)4[
M_&^6(]-JQ>IF)QD4*E+^ER=:R#DFPM,?F-C*MF7^GPQ@\:3=K+=GU_7<J@]:
MM3; Z+>:GKUI&TRTKN&D._.H-;ERD)MV'%L8%_;U<KSAL>RZM3S F[4HO@I
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M)<DI5G"<YQC/MP*5R(3NQ/GQ\7[L6SZ'IMIVSW'M=] V"D3M9=1=?7>W6$_
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M1%3[,=GX0AR<IQ\;8MU"?^2N^/'YI3<6]^#$< < < < < < < < < < < <
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MIK4,@6%RFFY >WV6UP%X5]6%9''B2VI6R5D3F\&8X X X X X X X X X X
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M?&PPX("$%16H0P0'%#V8\$:-'PV68L*##89C18[3;++:&T)3@9G=< < < <
M< < < < < < < < < < < < < QL['=.^K?;RNMU;LMH?6NY!D9EU@9(N5;A
MR[ !0_G.7E5>VQDQ;757W?DK[)-<-"Y*\*5A3N<*SC(E-JZ="![;'I2O'?;#
M&;'IV^=C^O!=F5B6+@U"_"K?6Q#R%_8PY#;OM<-W;#L9>$YCO?O]+J,8]U*6
MY\7$C18TM:-<4=]3/ OVLUTEH=1_.'WYK]:C^R(M>8+663"BL)_C#<6-+V\\
M'C*PGV3\XX9O'\8_I^V,8P(>(GGAQ\C*2I>%_,K+6>P?DI\GG8B%GV3/IQCM
M7:M<ZZ+-?^XU/KVO6Q1]S#F,Y0K*+BWE+><I3[*S\^"-O=&"_P":^=24[0_7
M[476;7D'5>D:@BE44?/(%61'ZW8[))?*E74O%"A$];3!ZPEB1%].'YL\H5F2
MY+WR=>>6XI2LBF=V>R< < < < < < < < < < < < < < < < < < < < <
M< < < < < < < < < < < < < KM>?#S*;$\7]>TO0M!U&CV?=>[&K:>69V#
M')EZ[0J14W@X[\_]N""P&47.V8L8>C@WI)5(D<U73#D\>26_%90-</#VZU=E
M3Q/+O3_>:K>?DJMV[]*=E:YKJ)L+6U0#[)I]KUT()5IFP51\ZU6K(/L(">:-
MQL$ I4M6W!Y00[!CR891Z--'(D1&IDX,3#4*-5HZYZ;O7H37=^>ZFL_'YU:V
M5V=V@VLF.IL*/ JU/B368!;8-^..9A5*D")#S4CZ'RY#.7R1!$.=D%78)NQ/
M09441(:4,XQ<FDM>W$I7Z)]4QY$=G=J-552;JKKP6U_LO;5*HB=6@:C;H1K]
M*N5J&UV/!!723>)Q#%JPT1;3$+$1\X0Z4]GG:WB&O$!L=#P8J+=75)NNEENW
M=S8%R"0Z(ZEB5/A1GUI2I#,B4PRZM*E92E26W'$K4E2DJ2G.,9QE6,XQ_.,\
M',<W@'5J.!4*4A9@6A:<YPI*B$1*DYQ_MPI.7L9QG'^>,X]^ =BVZV\VAUEQ
M#K3B<+;=;6E;;B%8]TK0M.<I4E6,^^%)SG&<?SC/ .,LB/;D)B.3H:)2U82B
M,N2RF0M2O]U*6<KPXI2O?^,83G.?\N ?[.(0!<5V:3FQ!T)G&,O2YTEF)%:Q
MG/MC+LB0MMIO&<_QC*EX_G@' #V2NV)#KE?/!3C;"L)?6'*02:&5*]_BEU4)
M]]+:L^V?;"\XSGVS[?[,\ K'^??R\]UO&!M_0(;0->T@6UGN/6UE)N2-G4BU
MV(RW>J39T1;&Q!(@K_5(B!:0%FI;B(3@]^2S+<EOKF+:E,L1QMAX<9IU;JGH
MU[,L&=4=Q.]ANK_73?4A$%F9N?1NJMHD(XU#C4"&3O5&!V4I!B,O/R7F&()
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M;AJV^5R@A"%B*Z_$2)5>*4^Q*KXAB84<JSL:"7%&#+$14*ON#@^"CS31-AQ
MC!DDY)NE:.KX5K?Q\SS&O>JUL@#KM6]34;HQ;5]E:[KD-0!LE^VKFZ]AVP,
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.._P#QW4?^B0O^UP<Y_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
